Physician profile
Mian Rizwan
NPI 1437380276
$1,438.50
in general payments reported to CMS, 2019-2025
21 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.72 · 2021: $50.65 · 2022: $100 · 2023: $108 · 2024: $213 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.88 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $307.69 | 2024-2025 | Krystexxa, Otezla, Uplizna |
| Janssen Biotech, INC. | $127.35 | 2025 | Tremfya |
| Horizon Therapeutics Plc | $120.33 | 2020-2023 | Krystexxa |
| Actelion Pharmaceuticals US, INC. | $108.52 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Glaxosmithkline, LLC. | $96.60 | 2024-2025 | Benlysta, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $79.23 | 2025 | |
| Tersera Therapeutics LLC | $76.71 | 2025 | Quzyttir |
| Verona Pharma, INC. | $71.74 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.51 | 2024-2025 | Jardiance, Jascayd |
| Ucb, INC. | $47.58 | 2021-2025 | Bimzelx |
| Abbvie INC. | $38.78 | 2025 | |
| Genentech, INC. | $38.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.75 | 2025 | Saphnelo |
| United Therapeutics Corporation | $29.20 | 2025 | Tyvaso |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $29.04 | 2025 | Tymlos |
| Medtronic, INC. | $29.02 | 2025 | Intellis Adaptivestim |
| Sobi, INC | $19.25 | 2025 | |
| Scilex Pharmaceuticals INC. | $17.34 | 2024 | |
| Mallinckrodt Hospital Products INC. | $14.41 | 2025 | Acthar |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mian Rizwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.